CELC vs ZBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZBIO Captures Institutional Edge (2โ1 Pillars ยท 3โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while CELC counters with relative strength in Growth & Margin. Fundamentally, CELC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, CELC sits in BREAKDOWN (60th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CELC | ZBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.1B | $1.9B | Larger Scale | CELC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -100.0% | Higher Growth | CELC |
| Operating Margin (TTM) Profitability | 0.0% | -2747.5% | Higher Margin | CELC |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -1192.9% | -265.1% | Higher ROE | ZBIO |
| 52-Week Range Position Momentum | 7% ($54โ$151) | 46% ($14โ$45) | Stronger Trend | ZBIO |
| Beta / 30D Volatility Risk Regime | 1.28ฮฒ ยท 59% Vol | 1.16ฮฒ ยท 59% Vol | Lower Realized Risk | Tie |
| Unified Institutional Score Composite Signal | 39.7 / 100 (SELL) | 49.4 / 100 (HOLD) | Higher Composite | ZBIO |